Plus Therapeutics (NASDAQ:PSTV) Given New $21.00 Price Target at Ascendiant Capital Markets

Plus Therapeutics (NASDAQ:PSTV) had its price objective raised by Ascendiant Capital Markets from $20.50 to $21.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Saturday, September 27th. Wall Street Zen raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. Maxim Group cut their price target on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, August 18th. Finally, D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of Plus Therapeutics in a report on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Plus Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.00.

Plus Therapeutics Stock Performance

Plus Therapeutics stock opened at $0.89 on Monday. The stock has a market capitalization of $88.29 million, a price-to-earnings ratio of -0.40 and a beta of 0.81. Plus Therapeutics has a 52-week low of $0.16 and a 52-week high of $2.31. The stock’s 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.55.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $1.08 million. On average, equities research analysts forecast that Plus Therapeutics will post -2.3 EPS for the current year.

Insider Buying and Selling

In related news, Director Robert P. Lenk purchased 110,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average cost of $0.49 per share, with a total value of $53,900.00. Following the transaction, the director owned 139,327 shares of the company’s stock, valued at $68,270.23. This represents a 375.08% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.79% of the company’s stock.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 0.24% of Plus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.